Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trials
Christopher R. King,Debra Freeman,Irving D. Kaplan,Donald B. Fuller,Giampaolo Bolzicco,Sean P. Collins,Robert J. Meier,Jason Wang,Patrick A. Kupelian,Michael L. Steinberg,Alan W. Katz +10 more
Reads0
Chats0
TLDR
PSA relapse-free survival rates after SBRT compare favorably with other definitive treatments for low and intermediate risk patients, and the current evidence supports consideration of S BRT among the therapeutic options for these patients.About:
This article is published in Radiotherapy and Oncology.The article was published on 2013-11-01 and is currently open access. It has received 394 citations till now. The article focuses on the topics: PSA Failure & Androgen deprivation therapy.read more
Citations
More filters
Journal ArticleDOI
Stereotactic body radiotherapy using a hydrogel spacer for localized prostate cancer: A dosimetric comparison between tomotherapy with the newly-developed tumor-tracking system and cyberknife.
TL;DR: In this article, the authors evaluated the characteristics of tomotherapy plans with the tumor tracking system and compared them with cyberknife SBRT plans for localized prostate cancer using a hydrogel spacer.
Book ChapterDOI
Summary of Ongoing Prospective Trials Using SBRT for Prostate Cancer
Kirsty Morrison,Nicholas van As +1 more
TL;DR: This chapter summarises ongoing prospective trials which will contribute to existing data, potentially leading to further advances in prostate SBRT and large randomized trials, which will directly compare outcomes with conventional treatments.
Journal ArticleDOI
Health-related quality of life of salvage prostate reirradiation using stereotactic ablative radiotherapy with urethral-sparing
Carlo Greco,Oriol Pares,N. Pimentel,V. Louro,Beatriz Nunes,Justyna Kociolek,João Marques,Zvi Fuks +7 more
TL;DR: Pursuit of local control in intraprostatic failures is feasible and can be achieved with an acceptably low toxicity profile associated with effective OAR sparing.
Hypofractionated radiotherapy for prostate cancer: how far can we go?
TL;DR: This thesis investigated the feasibility of moderate and extreme hypofractionated radiotherapy for prostate cancer with emphasis on treatment induced side effects, using patient self-assessment questionnaires (PSAQ).
Journal ArticleDOI
Stereotactic prostate radiotherapy with or without androgen deprivation therapy, study protocol for a phase III, multi-institutional randomized-controlled trial
Marco Lorenzo Bonù,Alessandro Magli,Davide Tomasini,Francesco Frassine,Domenico Albano,Stefano Arcangeli,Alessia Bruni,Stefano Ciccarelli,Martina De Angeli,Giulio Francolini,Ciro Franzese,Paolo Ghirardelli,Luigi Grazioli,Andrea Emanuele Guerini,Andrea Lancia,Giulia Marvaso,M. Sepulcri,Luca Eolo Trodella,Vittorio Morelli,Andrea Georgopulos,Anastasiya Oleksandrivna Domina,Lorenzo Granello,Eneida Mataj,F. Barbera,Luca Triggiani +24 more
TL;DR: The Stereotactic Prostate radiotherapy with or without Androgen deprivation therapy trial (SPA Trial) as discussed by the authors was designed to establish a new standard of care for SRT in localized unfavorable intermediate and a subclass of localized high risk prostate cancer.
References
More filters
Journal ArticleDOI
Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer.
TL;DR: Significant late bladder and rectal toxicities from SBRT for prostate cancer are infrequent and the current evidence supports consideration of stereotactic body radiotherapy among the therapeutic options for localized prostate cancer.
Journal ArticleDOI
Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience.
TL;DR: The outcomes after high-dose hypofractionation were acceptable in the entire cohort of patients treated with the schedule of 70 at 2.5 Gy/fraction and the 5-year nadir + 2 ng/mL rate was 83% (95% confidence interval, 79–86%).
Journal ArticleDOI
Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: First clinical trial results
TL;DR: In this paper, the feasibility and toxicity of stereotactic hypofractionated accurate radiotherapy (SHARP) for localized prostate cancer were evaluated in a Phase I/II trial with 40 patients.
Journal ArticleDOI
Randomized trial comparing two fractionation schedules for patients with localized prostate cancer.
Himu Lukka,Charles Hayter,Jim A. Julian,Padraig Warde,W. James Morris,Mary Gospodarowicz,Mark Levine,Jinka Sathya,Richard Choo,Hugh M. Prichard,Michael Brundage,Winkle Kwan +11 more
TL;DR: This study was designed as a noninferiority investigation with a predefined tolerance of −7.5%.
Journal ArticleDOI
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial
David P. Dearnaley,Isabel Syndikus,Georges Sumo,M. Bidmead,D. Bloomfield,Catharine H. Clark,Annie Gao,Shama Hassan,Alan Horwich,Robert Huddart,Vincent Khoo,Peter Kirkbride,Helen Mayles,P. Mayles,O. Naismith,Chris Parker,Helen Patterson,Martin J. Russell,Christopher D Scrase,C. South,John Staffurth,Emma Hall +21 more
TL;DR: A pre-planned preliminary safety analysis of side-effects in stages 1 and 2 of a randomised trial comparing standard and hypofractionated radiotherapy seems equally well tolerated as conventionally fractionated treatment at 2 years.
Related Papers (5)
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
David P. Dearnaley,Isabel Syndikus,Helen Mossop,Vincent Khoo,Alison Birtle,D. Bloomfield,John Graham,Peter Kirkbride,John P Logue,Zafar Malik,Julian Money-Kyrle,Joe M. O'Sullivan,Miguel Panades,Chris Parker,Helen Patterson,Christopher D Scrase,John Staffurth,Andrew Stockdale,Jean Tremlett,M. Bidmead,Helen Mayles,O. Naismith,C. South,Annie Gao,Clare Cruickshank,Shama Hassan,Julia Pugh,Clare Griffin,Emma Hall +28 more
Fractionation and protraction for radiotherapy of prostate carcinoma
David J. Brenner,Eric J. Hall +1 more